Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8407117rdf:typepubmed:Citationlld:pubmed
pubmed-article:8407117lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:8407117lifeskim:mentionsumls-concept:C0023820lld:lifeskim
pubmed-article:8407117lifeskim:mentionsumls-concept:C0087093lld:lifeskim
pubmed-article:8407117lifeskim:mentionsumls-concept:C0001721lld:lifeskim
pubmed-article:8407117lifeskim:mentionsumls-concept:C0332237lld:lifeskim
pubmed-article:8407117lifeskim:mentionsumls-concept:C1522168lld:lifeskim
pubmed-article:8407117pubmed:issue2lld:pubmed
pubmed-article:8407117pubmed:dateCreated1993-11-15lld:pubmed
pubmed-article:8407117pubmed:abstractTextConflicting observations have been reported about the effects of topically administered timolol maleate on serum lipoproteins. We therefore considered this issue in a series of eight glaucoma patients receiving timolol maleate. Cholesterol and triglycerides were measured in plasma and in low-density lipoproteins (LDL), and high-density lipoproteins (HDL), both before and following three months of treatment. Following the treatment, the mean atherogenic index was increased from 2.72 to 3.38 (p = 0.012). This suggests that the atherogenic index should be determined before and during timolol maleate treatment in high-risk cardiovascular patients.lld:pubmed
pubmed-article:8407117pubmed:languageenglld:pubmed
pubmed-article:8407117pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8407117pubmed:citationSubsetIMlld:pubmed
pubmed-article:8407117pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8407117pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8407117pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8407117pubmed:statusMEDLINElld:pubmed
pubmed-article:8407117pubmed:monthAprlld:pubmed
pubmed-article:8407117pubmed:issn0165-5701lld:pubmed
pubmed-article:8407117pubmed:authorpubmed-author:SafranA BABlld:pubmed
pubmed-article:8407117pubmed:authorpubmed-author:JamesRRlld:pubmed
pubmed-article:8407117pubmed:authorpubmed-author:PomettaDDlld:pubmed
pubmed-article:8407117pubmed:authorpubmed-author:SimonsPPlld:pubmed
pubmed-article:8407117pubmed:authorpubmed-author:SansonettiAAlld:pubmed
pubmed-article:8407117pubmed:issnTypePrintlld:pubmed
pubmed-article:8407117pubmed:volume17lld:pubmed
pubmed-article:8407117pubmed:ownerNLMlld:pubmed
pubmed-article:8407117pubmed:authorsCompleteYlld:pubmed
pubmed-article:8407117pubmed:pagination109-10lld:pubmed
pubmed-article:8407117pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8407117pubmed:meshHeadingpubmed-meshheading:8407117-...lld:pubmed
pubmed-article:8407117pubmed:meshHeadingpubmed-meshheading:8407117-...lld:pubmed
pubmed-article:8407117pubmed:meshHeadingpubmed-meshheading:8407117-...lld:pubmed
pubmed-article:8407117pubmed:meshHeadingpubmed-meshheading:8407117-...lld:pubmed
pubmed-article:8407117pubmed:meshHeadingpubmed-meshheading:8407117-...lld:pubmed
pubmed-article:8407117pubmed:meshHeadingpubmed-meshheading:8407117-...lld:pubmed
pubmed-article:8407117pubmed:meshHeadingpubmed-meshheading:8407117-...lld:pubmed
pubmed-article:8407117pubmed:meshHeadingpubmed-meshheading:8407117-...lld:pubmed
pubmed-article:8407117pubmed:meshHeadingpubmed-meshheading:8407117-...lld:pubmed
pubmed-article:8407117pubmed:meshHeadingpubmed-meshheading:8407117-...lld:pubmed
pubmed-article:8407117pubmed:meshHeadingpubmed-meshheading:8407117-...lld:pubmed
pubmed-article:8407117pubmed:year1993lld:pubmed
pubmed-article:8407117pubmed:articleTitleTopical timolol maleate might adversely affect serum lipoproteins.lld:pubmed
pubmed-article:8407117pubmed:affiliationDepartment of Ophthalmology, Geneva University Hospital, Switzerland.lld:pubmed
pubmed-article:8407117pubmed:publicationTypeJournal Articlelld:pubmed